<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02116361</url>
  </required_header>
  <id_info>
    <org_study_id>191622-135</org_study_id>
    <nct_id>NCT02116361</nct_id>
  </id_info>
  <brief_title>OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females</brief_title>
  <official_title>BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of onabotulinumtoxinA (BOTOX®) compared with
      placebo as treatment for major depressive disorder (MDD) in adult females.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 22, 2014</start_date>
  <completion_date type="Actual">December 22, 2016</completion_date>
  <primary_completion_date type="Actual">August 25, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline Values for the Clinic 10-Item Montgomery-Asberg Depression Rating Scale (MADRS) Total Score</measure>
    <time_frame>Baseline</time_frame>
    <description>The MADRS is a 10-item scale completed by clinic personnel that assesses the subject's symptoms of depression. Each question is answered on a 7-point scale ranging from no symptoms to worst possible symptoms. The total score is summed for all responses and ranges from 0 to 60. A negative change from baseline indicates an improvement in symptoms and a positive change from baseline indicates a worsening.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline Values in the Clinic 10-Item Montgomery-Asberg Depression Rating Scale (MADRS) Total Score</measure>
    <time_frame>Week 6</time_frame>
    <description>The MADRS is a 10-item scale completed by clinic personnel that assesses the subject's symptoms of depression. Each question is answered on a 7-point scale ranging from no symptoms to worst possible symptoms. The total score is summed for all responses and ranges from 0 to 60. A negative change from baseline indicates an improvement in symptoms and a positive change from baseline indicates a worsening.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline Values for the 7-Item Clinical Global Impression of Severity of Illness (CGI-S) Score</measure>
    <time_frame>Baseline</time_frame>
    <description>The CGI-S is a 7-point scale assessed by the clinician to rate the severity of the subject's symptoms. Scores range from 1 to 7, from normal (1, not at all ill) to among the most extremely ill patients (7). A negative change from baseline indicates an improvement in symptoms and a positive change from baseline indicates a worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Values in the 7-Item Clinical Global Impression of Severity of Illness (CGI-S) Score</measure>
    <time_frame>24 Weeks</time_frame>
    <description>The CGI-S is a 7-point scale assessed by the clinician to rate the severity of the subject's symptoms. Scores range from 1 to 7, from normal (1, not at all ill) to among the most extremely ill patients (7). A negative change from baseline indicates an improvement in symptoms and a positive change from baseline indicates a worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Values in the Clinic Hamilton Depression Rating Scale 17-Item Version (HAM-D17)</measure>
    <time_frame>Baseline</time_frame>
    <description>The HAM-D17 is assessed by the clinician based on subject interview. The total scores range from 0 to 53. A higher total score indicates more severe depression. A negative change from baseline indicates an improvement in symptoms and a positive change from baseline indicates a worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Values in the Clinic Hamilton Depression Rating Scale 17-Item Version (HAM-D17)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>The HAM-D17 is assessed by the clinician based on subject interview. The total scores range from 0 to 53. A higher total score indicates more severe depression. A negative change from baseline indicates an improvement in symptoms and a positive change from baseline indicates a worsening.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">258</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>Placebo for onabotulinumtoxinA 50 U</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (normal saline) for onabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>onabotulinumtoxinA 50 U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for onabotulinumtoxinA 30 U</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (normal saline) for onabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>onabotulinumtoxinA 30 U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>onabotulinumtoxinA</intervention_name>
    <description>OnabotulinumtoxinA injected into protocol-specified areas on Day 1.</description>
    <arm_group_label>onabotulinumtoxinA 50 U</arm_group_label>
    <arm_group_label>onabotulinumtoxinA 30 U</arm_group_label>
    <other_name>BOTOX®</other_name>
    <other_name>botulinum toxin Type A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Placebo (normal saline) injected into protocol-specified areas on Day 1.</description>
    <arm_group_label>Placebo for onabotulinumtoxinA 50 U</arm_group_label>
    <arm_group_label>Placebo for onabotulinumtoxinA 30 U</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe major depressive disorder

        Exclusion Criteria:

          -  Prior treatment with botulinum toxin of any serotype for any reason

          -  Use of antidepressant medication for depression within 2 weeks of study

          -  Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shobhal Patel</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Woodland International Research Group</name>
      <address>
        <city>Little Rock</city>
        <state>Alaska</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CITrials</name>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <zip>90706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research/Comprehensive Clinical Development, Inc.</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network Inc.</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Behavioral Research Specialists, LLC</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Excell Research, Inc.</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NRC Research Institute</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schuster Medical Research Institute</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarkis Clinical Trials</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research LLC-North Clinic</name>
      <address>
        <city>Leesburg</city>
        <state>Florida</state>
        <zip>34748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Centers of America, LLC</name>
      <address>
        <city>Oakland Park</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stedman Clinical Trials</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Advanced Medical Research</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta, LLC</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uptown Research Institute, LLC</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Medicine Associates, LLC</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Clinical Trials, LLC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrative Clinical Trials</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPRI Clinical Trials</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Finger Lakes Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPS Research Company</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Clinical Research Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Research Network (Oregon) Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, INC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KRK Medical Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InSite Clinical Research</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Clinical Research Services Unit</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zain Research LLC</name>
      <address>
        <city>Richland</city>
        <state>Washington</state>
        <zip>99352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2014</study_first_submitted>
  <study_first_submitted_qc>April 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2014</study_first_posted>
  <results_first_submitted>November 21, 2017</results_first_submitted>
  <results_first_submitted_qc>November 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 19, 2017</results_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo (Normal Saline) for onabotulinumtoxinA 50 U</title>
          <description>Placebo (normal saline) for onabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>onabotulinumtoxinA 50 U</title>
          <description>OnabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Placebo (Normal Saline) for onabotulinumtoxinA 30 U</title>
          <description>Placebo (normal saline) for onabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>onabotulinumtoxinA 30 U</title>
          <description>OnabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="59"/>
                <participants group_id="P4" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal Reasons</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Decision - Relapse</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Modified Intent to Treat: Enrolled subjects who received treatment</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo (Normal Saline) for onabotulinumtoxinA 50 U</title>
          <description>Placebo (normal saline) for onabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>onabotulinumtoxinA 50 U</title>
          <description>OnabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Placebo (Normal Saline) for onabotulinumtoxinA 30 U</title>
          <description>Placebo (normal saline) for onabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>onabotulinumtoxinA 30 U</title>
          <description>OnabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="67"/>
            <count group_id="B2" value="65"/>
            <count group_id="B3" value="58"/>
            <count group_id="B4" value="65"/>
            <count group_id="B5" value="255"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="255"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Baseline Values for the Clinic 10-Item Montgomery-Asberg Depression Rating Scale (MADRS) Total Score</title>
        <description>The MADRS is a 10-item scale completed by clinic personnel that assesses the subject's symptoms of depression. Each question is answered on a 7-point scale ranging from no symptoms to worst possible symptoms. The total score is summed for all responses and ranges from 0 to 60. A negative change from baseline indicates an improvement in symptoms and a positive change from baseline indicates a worsening.</description>
        <time_frame>Baseline</time_frame>
        <population>Modified Intent to Treat: Enrolled subjects who received treatment with data at the noted time point</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Normal Saline) for onabotulinumtoxinA 30 U</title>
            <description>Placebo (normal saline) for onabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>onabotulinumtoxinA 30 U</title>
            <description>OnabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Normal Saline) for onabotulinumtoxinA 50 U</title>
            <description>Placebo (normal saline) for onabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>onabotulinumtoxinA 50 U</title>
            <description>OnabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Values for the Clinic 10-Item Montgomery-Asberg Depression Rating Scale (MADRS) Total Score</title>
          <description>The MADRS is a 10-item scale completed by clinic personnel that assesses the subject's symptoms of depression. Each question is answered on a 7-point scale ranging from no symptoms to worst possible symptoms. The total score is summed for all responses and ranges from 0 to 60. A negative change from baseline indicates an improvement in symptoms and a positive change from baseline indicates a worsening.</description>
          <population>Modified Intent to Treat: Enrolled subjects who received treatment with data at the noted time point</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4" spread="3.99"/>
                    <measurement group_id="O2" value="32.0" spread="4.12"/>
                    <measurement group_id="O3" value="32.4" spread="5.34"/>
                    <measurement group_id="O4" value="32.0" spread="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Values in the Clinic 10-Item Montgomery-Asberg Depression Rating Scale (MADRS) Total Score</title>
        <description>The MADRS is a 10-item scale completed by clinic personnel that assesses the subject's symptoms of depression. Each question is answered on a 7-point scale ranging from no symptoms to worst possible symptoms. The total score is summed for all responses and ranges from 0 to 60. A negative change from baseline indicates an improvement in symptoms and a positive change from baseline indicates a worsening.</description>
        <time_frame>Week 6</time_frame>
        <population>Modified Intent to Treat: Enrolled subjects who received treatment with data at the noted time point</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Normal Saline) for onabotulinumtoxinA 30 U</title>
            <description>Placebo (normal saline) for onabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>onabotulinumtoxinA 30 U</title>
            <description>OnabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Normal Saline) for onabotulinumtoxinA 50 U</title>
            <description>Placebo (normal saline) for onabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>onabotulinumtoxinA 50 U</title>
            <description>OnabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Values in the Clinic 10-Item Montgomery-Asberg Depression Rating Scale (MADRS) Total Score</title>
          <description>The MADRS is a 10-item scale completed by clinic personnel that assesses the subject's symptoms of depression. Each question is answered on a 7-point scale ranging from no symptoms to worst possible symptoms. The total score is summed for all responses and ranges from 0 to 60. A negative change from baseline indicates an improvement in symptoms and a positive change from baseline indicates a worsening.</description>
          <population>Modified Intent to Treat: Enrolled subjects who received treatment with data at the noted time point</population>
          <units>Scores on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" spread="1.4"/>
                    <measurement group_id="O2" value="-11.6" spread="1.4"/>
                    <measurement group_id="O3" value="-12.9" spread="1.2"/>
                    <measurement group_id="O4" value="-11.5" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Values for the 7-Item Clinical Global Impression of Severity of Illness (CGI-S) Score</title>
        <description>The CGI-S is a 7-point scale assessed by the clinician to rate the severity of the subject's symptoms. Scores range from 1 to 7, from normal (1, not at all ill) to among the most extremely ill patients (7). A negative change from baseline indicates an improvement in symptoms and a positive change from baseline indicates a worsening.</description>
        <time_frame>Baseline</time_frame>
        <population>Modified Intent to Treat: Enrolled subjects who received treatment with data at the noted time point</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Normal Saline) for onabotulinumtoxinA 30 U</title>
            <description>Placebo (normal saline) for onabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>onabotulinumtoxinA 30 U</title>
            <description>OnabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Normal Saline) for onabotulinumtoxinA 50 U</title>
            <description>Placebo (normal saline) for onabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>onabotulinumtoxinA 50 U</title>
            <description>OnabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Values for the 7-Item Clinical Global Impression of Severity of Illness (CGI-S) Score</title>
          <description>The CGI-S is a 7-point scale assessed by the clinician to rate the severity of the subject's symptoms. Scores range from 1 to 7, from normal (1, not at all ill) to among the most extremely ill patients (7). A negative change from baseline indicates an improvement in symptoms and a positive change from baseline indicates a worsening.</description>
          <population>Modified Intent to Treat: Enrolled subjects who received treatment with data at the noted time point</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="0.43"/>
                    <measurement group_id="O2" value="4.4" spread="0.53"/>
                    <measurement group_id="O3" value="4.4" spread="0.53"/>
                    <measurement group_id="O4" value="4.5" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Values in the 7-Item Clinical Global Impression of Severity of Illness (CGI-S) Score</title>
        <description>The CGI-S is a 7-point scale assessed by the clinician to rate the severity of the subject's symptoms. Scores range from 1 to 7, from normal (1, not at all ill) to among the most extremely ill patients (7). A negative change from baseline indicates an improvement in symptoms and a positive change from baseline indicates a worsening.</description>
        <time_frame>24 Weeks</time_frame>
        <population>Modified Intent to Treat: Enrolled subjects who received treatment with data at the noted time point</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Normal Saline) for onabotulinumtoxinA 30 U</title>
            <description>Placebo (normal saline) for onabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>onabotulinumtoxinA 30 U</title>
            <description>OnabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Normal Saline) for onabotulinumtoxinA 50 U</title>
            <description>Placebo (normal saline) for onabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>onabotulinumtoxinA 50 U</title>
            <description>OnabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Values in the 7-Item Clinical Global Impression of Severity of Illness (CGI-S) Score</title>
          <description>The CGI-S is a 7-point scale assessed by the clinician to rate the severity of the subject's symptoms. Scores range from 1 to 7, from normal (1, not at all ill) to among the most extremely ill patients (7). A negative change from baseline indicates an improvement in symptoms and a positive change from baseline indicates a worsening.</description>
          <population>Modified Intent to Treat: Enrolled subjects who received treatment with data at the noted time point</population>
          <units>Scores on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="0.2"/>
                    <measurement group_id="O2" value="-1.9" spread="0.2"/>
                    <measurement group_id="O3" value="-2.6" spread="0.2"/>
                    <measurement group_id="O4" value="-2.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Values in the Clinic Hamilton Depression Rating Scale 17-Item Version (HAM-D17)</title>
        <description>The HAM-D17 is assessed by the clinician based on subject interview. The total scores range from 0 to 53. A higher total score indicates more severe depression. A negative change from baseline indicates an improvement in symptoms and a positive change from baseline indicates a worsening.</description>
        <time_frame>Baseline</time_frame>
        <population>Modified Intent to Treat: Enrolled subjects who received treatment with data at the noted time point</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Normal Saline) for onabotulinumtoxinA 30 U</title>
            <description>Placebo (normal saline) for onabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>onabotulinumtoxinA 30 U</title>
            <description>OnabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Normal Saline) for onabotulinumtoxinA 50 U</title>
            <description>Placebo (normal saline) for onabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>onabotulinumtoxinA 50 U</title>
            <description>OnabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Values in the Clinic Hamilton Depression Rating Scale 17-Item Version (HAM-D17)</title>
          <description>The HAM-D17 is assessed by the clinician based on subject interview. The total scores range from 0 to 53. A higher total score indicates more severe depression. A negative change from baseline indicates an improvement in symptoms and a positive change from baseline indicates a worsening.</description>
          <population>Modified Intent to Treat: Enrolled subjects who received treatment with data at the noted time point</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7" spread="3.15"/>
                    <measurement group_id="O2" value="24.5" spread="3.03"/>
                    <measurement group_id="O3" value="23.3" spread="2.94"/>
                    <measurement group_id="O4" value="23.0" spread="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Values in the Clinic Hamilton Depression Rating Scale 17-Item Version (HAM-D17)</title>
        <description>The HAM-D17 is assessed by the clinician based on subject interview. The total scores range from 0 to 53. A higher total score indicates more severe depression. A negative change from baseline indicates an improvement in symptoms and a positive change from baseline indicates a worsening.</description>
        <time_frame>24 Weeks</time_frame>
        <population>Modified Intent to Treat: Enrolled subjects who received treatment with data at the noted time point</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Normal Saline) for onabotulinumtoxinA 30 U</title>
            <description>Placebo (normal saline) for onabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>onabotulinumtoxinA 30 U</title>
            <description>OnabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Normal Saline) for onabotulinumtoxinA 50 U</title>
            <description>Placebo (normal saline) for onabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>onabotulinumtoxinA 50 U</title>
            <description>OnabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Values in the Clinic Hamilton Depression Rating Scale 17-Item Version (HAM-D17)</title>
          <description>The HAM-D17 is assessed by the clinician based on subject interview. The total scores range from 0 to 53. A higher total score indicates more severe depression. A negative change from baseline indicates an improvement in symptoms and a positive change from baseline indicates a worsening.</description>
          <population>Modified Intent to Treat: Enrolled subjects who received treatment with data at the noted time point</population>
          <units>Scores on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.5" spread="1.1"/>
                    <measurement group_id="O2" value="-13.4" spread="1.1"/>
                    <measurement group_id="O3" value="-16.1" spread="0.8"/>
                    <measurement group_id="O4" value="-17.4" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The Safety Population was used to assess AEs and SAEs and consisted of all randomized patients who received at least 1 injection of the study treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Normal Saline) for onabotulinumtoxinA 50 U</title>
          <description>Placebo (normal saline) for onabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>onabotulinumtoxinA 50 U</title>
          <description>OnabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Normal Saline) for onabotulinumtoxinA 30 U</title>
          <description>Placebo (normal saline) for onabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>onabotulinumtoxinA 30 U</title>
          <description>OnabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fibula Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Ligament Rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign Breast Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucination, Auditory</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Varicose Vein</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid Ptosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>URI</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Arlene Lum, PMP</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-5548</phone>
      <email>lum_arlene@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

